Figure 1.
Percentage of second stage T. b. gambiense patients treated according to drug used.
Eflornithine versus melarsoprol (2003–2009).
Figure 2.
Institutional rate use of eflornithine.
National Sleeping Sickness Control Programmes versus nongovernmental organizations (2003–2009).
Figure 3.
Evolution of reported cases of both forms of human African trypanosomiasis (1998–2009).
Figure 4.
Classification of human African trypanosomiasis-endemic countries according to cases reported in 2009.